227 related articles for article (PubMed ID: 27272555)
1. Fimasartan: A New Angiotensin Receptor Blocker.
Lee HY; Oh BH
Drugs; 2016 Jul; 76(10):1015-22. PubMed ID: 27272555
[TBL] [Abstract][Full Text] [Related]
2. PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives.
Angeli F; Verdecchia P; Trapasso M; Pane M; Signorotti S; Reboldi G
Expert Opin Drug Metab Toxicol; 2018 May; 14(5):533-541. PubMed ID: 29676941
[TBL] [Abstract][Full Text] [Related]
3. Fimasartan, a novel angiotensin II receptor antagonist.
Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.
Rhee MY; Baek SH; Kim W; Park CG; Park SW; Oh BH; Kim SH; Kim JJ; Shin JH; Yoo BS; Rim SJ; Ha JW; Doh JH; Ahn Y; Chae JK; Park JB; Kim SK; Kim CH
Drug Des Devel Ther; 2015; 9():2847-54. PubMed ID: 26082615
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.
Yi S; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2011 Jun; 57(6):682-9. PubMed ID: 21394036
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study.
Oh GC; Joo KW; Kim MA; Choi DJ; Kim YJ; Lee HY
Drug Des Devel Ther; 2020; 14():1341-1349. PubMed ID: 32308367
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
10. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
Bulitta JB; Paik SH; Chi YH; Kim TH; Shin S; Landersdorfer CB; Jiao Y; Yadav R; Shin BS
Eur J Pharm Sci; 2017 Sep; 107():32-44. PubMed ID: 28599987
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.
Park JB; Sung KC; Kang SM; Cho EJ
Am J Cardiovasc Drugs; 2013 Feb; 13(1):47-56. PubMed ID: 23344912
[TBL] [Abstract][Full Text] [Related]
12. Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial.
Kang MG; Kim KI; Ihm SH; Rhee MY; Sohn IS; Lee HY; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
Trials; 2019 Jul; 20(1):389. PubMed ID: 31262348
[TBL] [Abstract][Full Text] [Related]
13. The angiotensin II type 1 receptor blocker losartan in clinical practice: a review.
Gavras HP; Salerno CM
Clin Ther; 1996; 18(6):1058-67; discussion 1057. PubMed ID: 9001823
[TBL] [Abstract][Full Text] [Related]
14. Antiatherosclerotic effects of the novel angiotensin receptor antagonist Fimasartan on plaque progression and stability in a rabbit model: a double-blind placebo-controlled trial.
Lee JY; Lee CW; Kim WJ; Ahn JM; Park DW; Kang SJ; Lee SW; Kim YH; Son WC; Jung S; Park SW; Park SJ
J Cardiovasc Pharmacol; 2013 Aug; 62(2):229-36. PubMed ID: 23615162
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of fimasartan in Mexican patients with grade 1-2 essential hypertension.
Cardona-Muñoz EG; López-Alvarado A; Conde-Carmona I; Sánchez-Mejorada G; Pascoe-González S; Banda-Elizondo RG; García-Castillo A; González-Gálvez G; Velasco-Sánchez RG; Vidrio-Velázquez M; Leiva-Pons JL; Villeda-Espinosa E; Guerra-López A; Esturau-Santalo RM
Arch Cardiol Mex; 2017; 87(4):316-325. PubMed ID: 28209359
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia.
Rhee MY; Ahn T; Chang K; Chae SC; Yang TH; Shim WJ; Kang TS; Ryu JK; Nah DY; Park TH; Chae IH; Park SW; Lee HY; Tahk SJ; Yoon YW; Shim CY; Shin DG; Seo HS; Lee SY; Kim DI; Kwan J; Joo SJ; Jeong MH; Jeong JO; Sung KC; Kim SY; Kim SH; Chun KJ; Oh DJ
BMC Pharmacol Toxicol; 2017 Jan; 18(1):2. PubMed ID: 28057081
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers.
Jeon H; Lim KS; Shin KH; Kim J; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2012 Jan; 59(1):84-91. PubMed ID: 21934629
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats.
Kim TH; Shin S; Bashir M; Chi YH; Paik SH; Lee JH; Choi HJ; Choi JH; Yoo SD; Bulitta JB; Ma E; Joo SH; Shin BS
Xenobiotica; 2014 Oct; 44(10):913-25. PubMed ID: 24786684
[TBL] [Abstract][Full Text] [Related]
19. FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
Kim JY; Son JW; Park S; Yoo TH; Kim YJ; Ryu DR; Chin HJ
Trials; 2017 Dec; 18(1):632. PubMed ID: 29284530
[TBL] [Abstract][Full Text] [Related]
20. Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension.
Kim SY; Joo SJ; Shin MS; Kim C; Cho EJ; Sung KC; Kang SM; Kim DS; Lee SH; Hwang KK; Park JB
Medicine (Baltimore); 2016 May; 95(22):e3764. PubMed ID: 27258507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
